ExThera Medical

ExThera Medical is a clinical-stage medical device company pioneering a novel pathogen adsorption technology. Its core platform utilizes affinity blood filters with chemically-bonded, modified heparin to bind and remove pathogens, including viruses and bacteria, and circulating tumor cells directly from a patient's blood. The Seraph 100 filter received an Emergency Use Authorization (EUA) for COVID-19 during the pandemic and is now in clinical trials for broader bloodstream infections, while a second product, ONCObind, is in early development for metastatic cancer. The company is privately held, headquartered in Martinez, California, and is actively seeking investment for its next funding round.

Microbind Affinity Blood Filter platform using extracorporeal filters with chemically-bonded, modified heparin microbeads to adsorb pathogens and circulating tumor cells from blood.

ExThera competes in the extracorporeal blood purification space with companies like CytoSorbents (CytoSorb) and SeaStar Medical (Selective Cytopheretic Device), which also target inflammatory mediators in sepsis. ExThera's differentiation lies in its specific pathogen-adsorption mechanism targeting a broad range of infectious agents directly.